AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock
Aveo expects the gross proceeds from the offering to be approximately $44.6 million.
Pharmaceuticals, Biotechnology and Life Sciences
Aveo expects the gross proceeds from the offering to be approximately $44.6 million.
Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…
PHILADELPHIA NEEDS DATELINE–(BUSINESS WIRE)–#cdkl5–Understanding the patient voice is fundamental for therapy development. Companies need to ensure that what matters most…
Coverage initiated with “Buy” rating and €2,00 price target, based on gene therapy potential MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN)…
– Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO…
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX) a biotechnology company focused on improving cancer treatments by…
DUBLIN–(BUSINESS WIRE)–The “Global Gynecology Partnering 2010-2020: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering. Global Gynecology…
DUBLIN–(BUSINESS WIRE)–The “Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020” report has been added to ResearchAndMarkets.com’s offering. The…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of…
The saliva-based diagnostic test will be powered by smartphones to make rapid, low-cost testing more widely available. KITCHENER, Ontario–(BUSINESS WIRE)–Nicoya,…